
Diabetic Retinopathy- Pipeline Insight, 2024
Description
Diabetic Retinopathy- Pipeline Insight, 2024
DelveInsight’s, “Diabetic Retinopathy- Pipeline Insight, 2024” report provides comprehensive insights about 50+ companies and 55+ pipeline drugs in Diabetic Retinopathy pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Geography Covered
- Global coverage
Diabetic Retinopathy: Overview
Diabetic retinopathy (DR) is a microvascular disorder that occurs due to the long-term effects of diabetes mellitus. Diabetic retinopathy may lead to vision-threatening damage to the retina, eventually leading to blindness. It is the most common cause of severe vision loss in adults of working age groups in the western world. Early detection and timely intervention are the keys to avoiding blindness due to diabetic retinopathy.
Diabetic retinopathy is subdivided into non-proliferative and proliferative retinopathy. Macular edema can arise at any stage of the disease and threaten visual acuity. The main risk factors for the development and progression of diabetic retinopathy are long duration of diabetes and poor control of blood sugar and arterial blood pressure. Laser photocoagulation is an evidence-based treatment for proliferative retinopathy and macular edema.
Diabetic retinopathy is a microangiopathy of the retina. It involves changes in the vascular wall and the rheological properties of the blood. The combination of these factors leads to capillary occlusion and thereby to retinal ischemia and angiographically demonstrable leakage. The typical histopathological changes include loss of pericytes and endothelial cells and thickening of the basilar membrane. Microaneurysms, i.e., sites of outward ballooning of the capillary wall, are pathognomonic.
Multiple biochemical signal pathways are involved. The increased activity of protein kinase C and protein glycosylation lead to the formation of advanced glycation end products (AGE). These, in turn, lead to cell interactions involving vascular endothelial growth factor (VEGF) that cause neo-vascularization in the anterior and posterior segments of the eye, increased vascular permeability resulting in leakage, and collapse of the inner blood-retina barrier. AGE are taken exogenously in food and are also formed endogenously in greater quantities because of hypoglycemia; they seem to mediate nearly all complications of diabetes, including the vasoconstriction and inflammatory vessel wall changes that are associated with the formation of atheromatous plaques and influence the functioning of endothelial cells and macrophages. Inflammatory changes in the vessel wall are the target of the current therapeutic approach employing the intravitreous injection of glucocorticoids. Other growth factors that play a role in the pathogenesis of diabetic retinopathy include insulin-like growth factors I and II, transforming growth factor β, and pigment epithelium-derived growth factor.
""Diabetic Retinopathy- Pipeline Insight, 2024"" report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Diabetic Retinopathy pipeline landscape is provided which includes the disease overview and Diabetic Retinopathy treatment guidelines. The assessment part of the report embraces, in depth Diabetic Retinopathy commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Diabetic Retinopathy collaborations, licensing, mergers and acquisition, funding, designations and other product related details.
Report Highlights
- The companies and academics are working to assess challenges and seek opportunities that could influence Diabetic Retinopathy R&D. The therapies under development are focused on novel approaches to treat/improve Diabetic Retinopathy.
This segment of the Diabetic Retinopathy report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
Diabetic Retinopathy Emerging Drugs
- Brolucizumab: Novartis
Diabetic Retinopathy.
- RGX 314: Regenxbio Inc.
- OTT-166: OcuTerra Therapeutics
- OTX-TKI: Ocular Therapeutix
Further product details are provided in the report……..
Diabetic Retinopathy: Therapeutic Assessment
This segment of the report provides insights about the different Diabetic Retinopathy drugs segregated based on following parameters that define the scope of the report, such as:
- Major Players in Diabetic Retinopathy
- There are approx. 50+ key companies which are developing the therapies for Diabetic Retinopathy. The companies which have their Diabetic Retinopathy drug candidates in the most advanced stage, i.e. phase III include, Kodiak Sciences.
- Phases
- Late stage products (Phase III)
- Mid-stage products (Phase II)
- Early-stage product (Phase I) along with the details of
- Pre-clinical and Discovery stage candidates
- Discontinued & Inactive candidates
- Route of Administration
- Oral
- Intravenous
- Subcutaneous
- Parenteral
- Topical
- Molecule Type
- Recombinant fusion proteins
- Small molecule
- Monoclonal antibody
- Peptide
- Polymer
- Gene therapy
- Product Type
Diabetic Retinopathy: Pipeline Development Activities
The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Diabetic Retinopathy therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Diabetic Retinopathy drugs.
Diabetic Retinopathy Report Insights
- Diabetic Retinopathy Pipeline Analysis
- Therapeutic Assessment
- Unmet Needs
- Impact of Drugs
- Pipeline Product Profiles
- Therapeutic Assessment
- Pipeline Assessment
- Inactive drugs assessment
- Unmet Needs
Current Treatment Scenario and Emerging Therapies:
- How many companies are developing Diabetic Retinopathy drugs?
- How many Diabetic Retinopathy drugs are developed by each company?
- How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Diabetic Retinopathy?
- What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Diabetic Retinopathy therapeutics?
- What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
- What are the clinical studies going on for Diabetic Retinopathy and their status?
- What are the key designations that have been granted to the emerging drugs?
- Kodiak Sciences
- Novartis
- Regenxbio Inc.
- OcuTerra Therapeutics
- Ocular Therapeutix
- Bayer
- RemeGen
- Roche
- Ocuphire Pharma
- Adverum Biotechnologies
- Boehringer Ingelheim
- KSI-301
- Brolucizumab
- RGX 314
- OTT-166
- OTX-TKI
- Runcaciguat
- RC 28 E
- RG7774
- APX3330
- ADVM-022
- Faricimab
- BI 764524
Table of Contents
210 Pages
- Introduction
- Executive Summary
- Diabetic Retinopathy: Overview
- Causes
- Mechanism of Action
- Signs and Symptoms
- Diagnosis
- Disease Management
- Pipeline Therapeutics
- Comparative Analysis
- Therapeutic Assessment
- Assessment by Product Type
- Assessment by Stage and Product Type
- Assessment by Route of Administration
- Assessment by Stage and Route of Administration
- Assessment by Molecule Type
- Assessment by Stage and Molecule Type
- Diabetic Retinopathy– DelveInsight’s Analytical Perspective
- Late Stage Products (Phase III)
- Comparative Analysis
- KSI-301: Kodiak Sciences
- Product Description
- Research and Development
- Product Development Activities
- Drug profiles in the detailed report…..
- Mid Stage Products (Phase II)
- Comparative Analysis
- RGX 314: Regenxbio Inc
- Product Description
- Research and Development
- Product Development Activities
- Drug profiles in the detailed report…..
- Early Stage Products (Phase I)
- Comparative Analysis
- OTX-TKI: Ocular Therapeutix
- Product Description
- Research and Development
- Product Development Activities
- Drug profiles in the detailed report…..
- Preclinical and Discovery Stage Products
- Comparative Analysis
- Drug name: Company name
- Product Description
- Research and Development
- Product Development Activities
- Drug profiles in the detailed report…..
- Inactive Products
- Comparative Analysis
- Diabetic Retinopathy Key Companies
- Diabetic Retinopathy Key Products
- Diabetic Retinopathy- Unmet Needs
- Diabetic Retinopathy- Market Drivers and Barriers
- Diabetic Retinopathy- Future Perspectives and Conclusion
- Diabetic Retinopathy Analyst Views
- Diabetic Retinopathy Key Companies
- Appendix
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.